

CONFERENCE PROGRAM

Sunday, October 1

- 6:00 p.m.-8:00 p.m.** **OPENING KEYNOTE ADDRESSES AND SPECIAL LECTURE**
Salons EF
- 6:00 p.m.-6:45 p.m. **Principles of response and resistance to immunotherapy**
Levi A. Garraway, Eli Lilly and Company, Indianapolis, IN
- 6:45 p.m.-7:30 p.m. **Engineering T cells to eradicate tumors in the age of synthetic biology**
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
- 7:30 p.m.-8:00 p.m. **Immune checkpoint blockade in cancer therapy: New Insights, opportunities, and prospects for cures**
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
- 8:00 p.m.-9:30 p.m.** **OPENING RECEPTION**
Back Bay

Monday, October 2

- 7:00 a.m.-8:15 a.m.** **BREAKFAST AND MENTORING ROUNDTABLES**
Fairfield-Arlington
- 8:15 a.m.-9:45 a.m.** **SESSION 1: SINGLE-CELL IMAGING OF CANCER IMMUNOLOGY**
Salons EF
Session Chair: Matthew F. Krummel, University of California San Francisco, San Francisco, CA
- 8:15 a.m.-8:45 a.m. **Pathology from the molecular scale on up**
Garry P. Nolan, Stanford University, Stanford, CA
- 8:45 a.m.-9:15 a.m. **Tracking immune cells in sterile injury and how it pertains to cancer**
Paul Kubes, University of Calgary, Calgary, AB, Canada
- 9:15 a.m.-9:45 a.m. **Imaging- and single cell-based insights into effective antitumor immune responses**
Matthew F. Krummel
- 9:45 a.m.-10:15 a.m.** **BREAK**
Salons EF Foyer

**Short talk from proffered abstract*

CONFERENCE PROGRAM

10:15 a.m.-12:00 p.m.	SESSION 2: SYNTHETIC IMMUNOTHERAPY Salons EF Session Chair: Darrell J. Irvine , Koch Institute of MIT, Cambridge, MA
10:15 a.m.-10:45 a.m.	Enhancing combination immunotherapy and adoptive cell therapy of cancer via lymph node-targeted vaccines Darrell J. Irvine
10:45 a.m.-11:15 a.m.	Genetic engineering of therapeutic T cells using synthetic nanoparticles Matthias T. Stephan, Fred Hutchinson Cancer Research Center, Seattle, WA
11:15 a.m.-11:45 a.m.	Engineering T cells to resist and convert immunosuppressive tumor microenvironments Yvonne Y. Chen, University of California Los Angeles, Los Angeles, CA
11:45 a.m.-12:00 p.m.	Targeting multiple myeloma with universal SLAMF7-specific CAR T-cells* Rohit Mathur, The University of Texas MD Anderson Cancer Center, Houston, TX
12:00 p.m.-1:30 p.m.	LUNCH ON OWN/FREE TIME
1:30 p.m.-3:15 p.m.	SESSION 3: NEOANTIGENS: THE NEW BIOMARKERS Salons EF Session Chair: Catherine J. Wu , Dana-Farber Cancer Institute, Boston, MA
1:30 p.m.-2:00 p.m.	RiboSeq and ye shall find: Noncanonical protein translation in cancer immunosurveillance Jonathan W. Yewdell, National Institute of Allergy and Infectious Diseases, Bethesda, MD
2:00 p.m.-2:30 p.m.	Cell transfer immunotherapy targeting unique somatic mutations in cancer Steven A. Rosenberg, National Cancer Institute, Bethesda, MD
2:30 p.m.-3:00 p.m.	Developing and improving personalized neoantigen-targeting cancer vaccines Catherine J. Wu
3:00 p.m.-3:15 p.m.	Identification of breast cancer neoantigens exposed by radiation therapy* Claire Lhuillier, Weill Cornell Medical College, New York, NY
3:15 p.m.-3:45 p.m.	BREAK Salons EF Foyer
3:45 p.m.-5:30 p.m.	SESSION 4: A SYSTEMS APPROACH TO IMMUNO-ONCOLOGY Salons EF Session Chair: Dana Pe'er , Sloan Kettering Institute, New York, NY
3:45 p.m.-4:15 p.m.	Integrative genomics and immune contexture approach to immune-oncology Jérôme Galon, French National Institute of Health and Medical Research, Paris, France

**Short talk from proffered abstract*

CONFERENCE PROGRAM

- 4:15 p.m.-4:45 p.m. **Spatio-temporal quirks of IFN- γ regulation of immune responses in tumors**
Grégoire Altan-Bonnet, National Cancer Institute, Bethesda, MD
- 4:45 p.m.-5:15 p.m. **An atlas of the tumor immune ecosystem**
Dana Pe'er
- 5:15 p.m.-5:30 p.m. **Genetic mechanisms of immune evasion in colorectal cancer***
Marios Giannakis, Dana-Farber Cancer Institute and Harvard Medical School,
Boston, MA
- 5:30 p.m.-7:30 p.m.** **POSTER SESSION A/RECEPTION**
Back Bay

Tuesday, October 3

- 7:00 a.m.-8:00 a.m.** **BREAKFAST AND NETWORKING ROUNDTABLES**
Fairfield-Arlington
- 8:00 a.m.-9:45 a.m.** **SESSION 5: THE INFLAMMATORY TUMOR MICROENVIRONMENT**
Salons EF
Session Chair: Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY
- 8:00 a.m.-8:30 a.m. **Immune cell atlas of human lung cancer lesions**
Miriam Merad
- 8:30 a.m.-9:00 a.m. **Macrophages orchestrate early dissemination and metastasis**
Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, NY
- 9:00 a.m.-9:30 a.m. **Stromal microenvironments in cancer immunology**
Shannon J. Turley, Genentech, Inc., San Francisco, CA
- 9:30 a.m.-9:45 a.m. **Lymph node colonization promotes systemic tumor metastasis through induction of immune tolerance***
Nathan E. Reticker-Flynn, Stanford University, Stanford, CA
- 9:45 a.m.-10:00 a.m. **Preventing the recurrence of breast cancer at the metastatic niche using resolution-phase macrophages***
Dalit Barkan, University of Haifa, Haifa, Israel
- 10:00 a.m.-10:30 a.m.** **BREAK**
Salons EF Foyer

**Short talk from proffered abstract*

CONFERENCE PROGRAM

10:30 a.m.-12:00 p.m.	SESSION 6: ENGINEERING IMMUNE CELLS TO TREAT CANCER Salons EF Session Chair: Carl H. June , University of Pennsylvania, Philadelphia, PA
10:30 a.m.-11:00 a.m.	CAR therapy: Beyond the CD19 paradigm Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
11:00 a.m.-11:30 a.m.	New directions in T cell therapies for cancer Marcela V. Maus, Massachusetts General Hospital, Cancer Center, Boston, MA
11:30 a.m.-12:00 p.m.	Updates on CAR T cells Carl H. June
12:00 p.m.-2:30 p.m.	POSTER SESSION B/LUNCH Back Bay
2:30 p.m.-4:30 p.m.	SESSION 7: THE MICROBIOME IN CANCER IMMUNITY Salons EF Session Chair: Giorgio Trinchieri , National Cancer Institute, Bethesda, MD
2:30 p.m.-3:00 p.m.	Cancer and the microbiome Giorgio Trinchieri
3:00 p.m.-3:30 p.m.	<i>Fusobacterium nucleatum</i> and colon cancer Wendy S. Garrett, Harvard T.H. Chan School of Public Health, Boston, MA
3:30 p.m.-4:00 p.m.	Understanding response and resistance to cancer therapy: Lessons learned from melanoma Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX
4:00 p.m.-4:15 p.m.	Drugging the human microbiome for combination with tumor immunotherapy* David N. Cook, Seres Therapeutics, Cambridge, MA
4:15 p.m.-4:30 p.m.	<i>Fusobacterium</i> species, microsatellite instability, and exome-wide neoantigen load in relation to immune response to colorectal cancer* Shuji Ogino, Brigham and Women's Hospital, Boston, MA
4:30 p.m.-4:45 p.m.	BREAK Salons EF Foyer

**Short talk from proffered abstract*

CONFERENCE PROGRAM

- 4:45 p.m.-6:30 p.m.** **SESSION 8: METABOLIC REGULATION OF IMMUNE RESPONSES**
Salons EF
Session Chair: Luke A. J. O'Neill, Trinity College Dublin, Dublin, Ireland
- 4:45 p.m.-5:15 p.m. **Krebs cycle reprogrammed for cytokines**
Luke A. J. O'Neill
- 5:15 p.m.-5:45 p.m. **Identification of essential genes for cancer immunotherapy**
Nicholas P. Restifo, National Cancer Institute, Bethesda, MD
- 5:45 p.m.-6:15 p.m. **Immunometabolic circuits in myeloid cell reprogramming**
Mihai Netea, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- 6:15 p.m.-6:30 p.m. **Metabolic adaptations establish immunotherapy resistance in melanoma***
Ashvin R. Jaiswal, The University of Texas MD Anderson Cancer Center, Houston, TX

Wednesday, October 4

- 7:00 a.m.-8:00 a.m.** **BREAKFAST**
Fairfield-Arlington
- 8:00 a.m.-9:45 a.m.** **SESSION 9: NEW COMBINATION THERAPIES**
Salons EF
Session Chair: Sandra Demaria, Weill Cornell Medical College, New York, NY
- 8:00 a.m.-8:30 a.m. **Strategies to optimize the adjuvant role of radiotherapy during cancer immunotherapy**
Silvia C. Formenti, Weill Cornell Medical College, New York, NY
- 8:30 a.m.-9:00 a.m. **Cancer immunotherapy: Translational control of immune checkpoint**
Caroline Robert, Institut de Cancerologie Gustave Roussy, Villejuif, France
- 9:00 a.m.-9:30 a.m. **Novel insights into the dose-dependency of radiation immunogenicity**
Sandra Demaria
- 9:30 a.m.-9:45 a.m. **Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies***
Elizabeth E. Evans, Vaccinex, Rochester, NY
not eligible for CME credit
- 9:45 a.m.-10:15 a.m.** **BREAK**
Salons EF Foyer

**Short talk from proffered abstract*

CONFERENCE PROGRAM

10:15 a.m.-11:30 a.m.	SESSION 10: CHECKPOINTS AND IMMUNOMODULATION Salons EF Session Chair: Joshua D. Brody , Icahn School of Medicine at Mount Sinai, New York, NY
10:15 a.m.-10:45 a.m.	Regulatory T cells and radiation therapy Charles G. Drake, Columbia University Medical Center, New York, NY
10:45 a.m.-11:15 a.m.	Improving checkpoint blockade for lymphoma with Flt3L-primed in situ vaccination Joshua D. Brody
11:15 a.m.-11:30 a.m.	Cancer-germline antigens discriminate clinical outcome to CTLA4 blockade* Sachet Shukla, Dana-Farber Cancer Institute, Boston, MA
11:30 a.m.	CLOSING REMARKS AND DEPARTURE Salons EF

**Short talk from proffered abstract*